Stockreport

ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S. [Yahoo! Finance]

ProKidney Corp. - Class A Ordinary Shares  (PROK) 
PDF Discontinued the ex-U.S.-based PROACT 2 trial and focused Company resources on PROACT 1 to expedite enrollment and accelerate estimated topline data readout to Q3 2027 [Read more]